Last mentioned: Mar 20, 2026
Pipeline Integration
Expected completion of the asset transfer and full integration into Novartis's global oncology pipeline.
Acquisition Announcement
Novartis announces the acquisition of SNV4818 for a total deal value of up to $3 billion.
Synnovation Development
Synnovation Therapeutics advances SNV4818 through early clinical stages, showing promising medicinal chemistry results.
Novartis Spin-off
Novartis completes the spin-off of its Sandoz generics division to focus exclusively on innovative medicines.
Novartis AG has reached an agreement to acquire an experimental breast cancer treatment from Synnovation Therapeutics for a total consideration of up to $3 billion. The deal centers on SNV4818, a promising oncology candidate designed to strengthen Novartis's position in the highly competitive breast cancer market.
Novartis AG has entered into an agreement to acquire SNV4818, an experimental breast cancer drug from Synnovation Therapeutics, in a deal valued at up to $3 billion. This strategic move aims to strengthen Novartis's leadership in the oncology sector as it seeks to replenish its pipeline with high-potential targeted therapies.
Novartis AG has entered into a definitive agreement to acquire an experimental breast cancer drug candidate, SNV4818, from Delaware-based Synnovation Therapeutics for up to $3 billion. This strategic acquisition aims to strengthen Novartis's leadership in the oncology market as it continues its pivot toward high-value innovative medicines.